2024 · Analytical and bioanalytical chemistry · open access
Development and validation of the UHPLC-MS/MS method for the quantitative determination of 25 PFAS in dried blood spots
Galletto et al.
The finding, in our words
An analytical method using Capitainer B devices collecting 10 microlitres of capillary blood was successfully validated for the quantitative determination of 25 PFAS using UHPLC-MS/MS. The method demonstrated high recovery above 80% and met precision and accuracy criteria across the validated range of 2 to 100 ng/mL.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A validated two-step LC-MS/MS protocol can identify 91 prohibited doping agents from a single dried blood spot collected on either cellulose cards or volumetric absorptive microsampling devices. This demonstrates robust multi-analyte screening from capillary blood, supporting decentralised anti-doping programmes where venous sampling is impractical.
This study validated a method for measuring the alcohol biomarker phosphatidylethanol using two volumetric absorptive microsampling devices, finding that the Mitra device met all validation criteria and agreed with venous sampling. The Capitainer device was deemed suitable but showed reduced accuracy at higher concentrations, with a small proportional negative bias compared to venous results.
The authors found that a single microdose of recombinant EPO was detectable up to 72 hours using ITP and CP methods, though the Tasso microsampling device showed lower sensitivity than Mitra and Capitainer. Additionally, isotope ratio mass spectrometry successfully detected testosterone micro-dosing in all analysed samples, supported by serum testosterone levels.
Filtered protein precipitation was the most effective extraction method for 75 per- and polyfluoroalkyl substances from dried blood spots collected with a capillary microsampler, recovering 72 analytes within 70–130% with limits of detection from 0.05 to 0.34 ng/mL. The method detected 16 PFAS in self-collected human samples, demonstrating feasibility for large-scale biomonitoring studies using minimally invasive sampling.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.